Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin versus docetaxel in previously treated c-Met-overexpressing EGFR-wildtype non-squamous NSCLC
2021-001811-94Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Dec 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Telisotuzumab vedotin with Docetaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Dec 2021; status: active.
02
Drugs
telisotuzumab vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-001811-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001811-94.